University of Cagliari
Analysis of Early Events during the First Year of Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Phase - Chronic Myeloid Leukemia: A "Campus CML" Study
Mulas, Olga;Caocci, Giovanni;Specchia, Giorgina;
2021-01-01
Abstract
Tyrosine kinase inhibitors (TKIs) revolutionized treatment of chronic myeloid leukemia (CML). However, the rst months of therapy are crucial, as optimal response is dened as the achievement of molecular milestones at 3, 6 and 12 months (mo.) and as many toxicities, also causing a TKI switch, are more frequent in the 1st year
Files in This Item:
| File | Size | Format | |
|---|---|---|---|
| PDF abstracts 1-s2.0-S0006497121034595-main.pdf open access
Type: versione editoriale
Size 438.82 kB
Format Adobe PDF
|
438.82 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.